Cargando…

Knockdown of FUSE binding protein 1 enhances the sensitivity of epithelial ovarian cancer cells to carboplatin

Epithelial ovarian cancer (EOC) affects almost 25,000 women annually and is the fifth most common malignancy in women in North America. A combination of surgery and cytotoxic chemotherapy may produce a favorable clinical response. The platinum-paclitaxel combination regimen is the chemotherapy gold-...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jinli, Xiong, Xifeng, Hua, Xing, Cao, Wenjuan, Qin, Shengnan, Dai, Libing, Liang, Peihong, Zhang, Huiling, Liu, Zhihe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5661610/
https://www.ncbi.nlm.nih.gov/pubmed/29113212
http://dx.doi.org/10.3892/ol.2017.6978
_version_ 1783274515095093248
author Zhang, Jinli
Xiong, Xifeng
Hua, Xing
Cao, Wenjuan
Qin, Shengnan
Dai, Libing
Liang, Peihong
Zhang, Huiling
Liu, Zhihe
author_facet Zhang, Jinli
Xiong, Xifeng
Hua, Xing
Cao, Wenjuan
Qin, Shengnan
Dai, Libing
Liang, Peihong
Zhang, Huiling
Liu, Zhihe
author_sort Zhang, Jinli
collection PubMed
description Epithelial ovarian cancer (EOC) affects almost 25,000 women annually and is the fifth most common malignancy in women in North America. A combination of surgery and cytotoxic chemotherapy may produce a favorable clinical response. The platinum-paclitaxel combination regimen is the chemotherapy gold-standard for advanced ovarian cancer, and carboplatin is one of the agents in this combination therapy. However, the majority of patients eventually experience a relapse due to the development of platinum resistance. FUSE binding protein 1 (FBP1) has been identified as an anti-apoptotic and pro-proliferative oncoprotein that is overexpressed in hepatocellular carcinoma. Its high expression is also associated with carboplatin resistance. In the present study, it was identified that the expression of FBP1 was significantly higher in EOC tissues than in normal epithelial ovarian or in epithelial ovarian adenoma tissue. FBP1 expression was significantly correlated with the grade of epithelial ovarian cancer. Carboplatin inhibited the expression of FBP1 in epithelial ovarian cancer cells and the knockdown of FBP1 enhanced the inhibition of cell viability and migration by carboplatin. In addition to FBP1, carboplatin also inhibited the expression of β-catenin and matrix metalloproteinase (MMP)-9. Furthermore, the expression of β-catenin and MMP-9 were lower in FBP1 knockdown cells compared with control EOC cells. FBP1 may thus serve a role in the regulation of the expression of β-catenin and MMP-9; the inhibition of β-catenin and MMP-9 by carboplatin may be mediated through the inhibition of FBP1. The inhibition of FBP1 expression by carboplatin may be a mechanism in the treatment of EOC by carboplatin.
format Online
Article
Text
id pubmed-5661610
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-56616102017-11-06 Knockdown of FUSE binding protein 1 enhances the sensitivity of epithelial ovarian cancer cells to carboplatin Zhang, Jinli Xiong, Xifeng Hua, Xing Cao, Wenjuan Qin, Shengnan Dai, Libing Liang, Peihong Zhang, Huiling Liu, Zhihe Oncol Lett Articles Epithelial ovarian cancer (EOC) affects almost 25,000 women annually and is the fifth most common malignancy in women in North America. A combination of surgery and cytotoxic chemotherapy may produce a favorable clinical response. The platinum-paclitaxel combination regimen is the chemotherapy gold-standard for advanced ovarian cancer, and carboplatin is one of the agents in this combination therapy. However, the majority of patients eventually experience a relapse due to the development of platinum resistance. FUSE binding protein 1 (FBP1) has been identified as an anti-apoptotic and pro-proliferative oncoprotein that is overexpressed in hepatocellular carcinoma. Its high expression is also associated with carboplatin resistance. In the present study, it was identified that the expression of FBP1 was significantly higher in EOC tissues than in normal epithelial ovarian or in epithelial ovarian adenoma tissue. FBP1 expression was significantly correlated with the grade of epithelial ovarian cancer. Carboplatin inhibited the expression of FBP1 in epithelial ovarian cancer cells and the knockdown of FBP1 enhanced the inhibition of cell viability and migration by carboplatin. In addition to FBP1, carboplatin also inhibited the expression of β-catenin and matrix metalloproteinase (MMP)-9. Furthermore, the expression of β-catenin and MMP-9 were lower in FBP1 knockdown cells compared with control EOC cells. FBP1 may thus serve a role in the regulation of the expression of β-catenin and MMP-9; the inhibition of β-catenin and MMP-9 by carboplatin may be mediated through the inhibition of FBP1. The inhibition of FBP1 expression by carboplatin may be a mechanism in the treatment of EOC by carboplatin. D.A. Spandidos 2017-11 2017-09-15 /pmc/articles/PMC5661610/ /pubmed/29113212 http://dx.doi.org/10.3892/ol.2017.6978 Text en Copyright: © Zhang et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Zhang, Jinli
Xiong, Xifeng
Hua, Xing
Cao, Wenjuan
Qin, Shengnan
Dai, Libing
Liang, Peihong
Zhang, Huiling
Liu, Zhihe
Knockdown of FUSE binding protein 1 enhances the sensitivity of epithelial ovarian cancer cells to carboplatin
title Knockdown of FUSE binding protein 1 enhances the sensitivity of epithelial ovarian cancer cells to carboplatin
title_full Knockdown of FUSE binding protein 1 enhances the sensitivity of epithelial ovarian cancer cells to carboplatin
title_fullStr Knockdown of FUSE binding protein 1 enhances the sensitivity of epithelial ovarian cancer cells to carboplatin
title_full_unstemmed Knockdown of FUSE binding protein 1 enhances the sensitivity of epithelial ovarian cancer cells to carboplatin
title_short Knockdown of FUSE binding protein 1 enhances the sensitivity of epithelial ovarian cancer cells to carboplatin
title_sort knockdown of fuse binding protein 1 enhances the sensitivity of epithelial ovarian cancer cells to carboplatin
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5661610/
https://www.ncbi.nlm.nih.gov/pubmed/29113212
http://dx.doi.org/10.3892/ol.2017.6978
work_keys_str_mv AT zhangjinli knockdownoffusebindingprotein1enhancesthesensitivityofepithelialovariancancercellstocarboplatin
AT xiongxifeng knockdownoffusebindingprotein1enhancesthesensitivityofepithelialovariancancercellstocarboplatin
AT huaxing knockdownoffusebindingprotein1enhancesthesensitivityofepithelialovariancancercellstocarboplatin
AT caowenjuan knockdownoffusebindingprotein1enhancesthesensitivityofepithelialovariancancercellstocarboplatin
AT qinshengnan knockdownoffusebindingprotein1enhancesthesensitivityofepithelialovariancancercellstocarboplatin
AT dailibing knockdownoffusebindingprotein1enhancesthesensitivityofepithelialovariancancercellstocarboplatin
AT liangpeihong knockdownoffusebindingprotein1enhancesthesensitivityofepithelialovariancancercellstocarboplatin
AT zhanghuiling knockdownoffusebindingprotein1enhancesthesensitivityofepithelialovariancancercellstocarboplatin
AT liuzhihe knockdownoffusebindingprotein1enhancesthesensitivityofepithelialovariancancercellstocarboplatin